Glaukos is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker GKOS on the NYSE exchange.
Glaukos stock last closed at $106.64, down 2.59% from the previous day, and has decreased 30.28% in one year. It has overperformed other stocks in the Medical Devices industry by 0.54 percentage points. Glaukos stock is currently +45.76% from its 52-week low of $73.16, and -34.08% from its 52-week high of $161.78.
There are currently 57.43M GKOS shares outstanding. The market value of GKOS is $6.12B. In the last 24 hours, 1.26M GKOS shares were traded.
You will need an online brokerage account in order to access the NYSE market and buy GKOS stock.
In our opinion, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked the best brokerage, the next step is to fill out some personal information so you are able to invest in GKOS today.
Now that you have filled out your info on one of the most highly reviewed stock apps, your next step is to transfer the money for your investment:
Check out the video below if you need help depositing money into your investment account.
After you have decided on the best place to buy Glaukos stock, it's critical to research their stock prior to investing, so you actually understand the risk and opportunity.
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
You can view all of the due diligence checks on GKOS's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge GKOS's intrinsic value.
Using relative valuations ratios:
You can access more valuation analysis on GKOS's stock here.
Out of 10 Equities analysts who give forecasts on GKOS, the consensus analyst rating on Glaukos is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Richard Newitter, a top 12% analyst from Truist Securities maintains GKOS with a strong buy rating and raises their GKOS price target from $120.00 to $145.00, on Dec 18, 2025.
Truist Securities's Richard Newitter raised their price target on Glaukos (NYSE: GKOS) by 20.8% from $120 to $145 on 2025/12/18. The analyst maintained their Strong Buy rating on the stock.
In a 2026 preview note on names in their MedTech portfolio, Newitter expressed confidence in the group because of "a more attractive relative sector valuation."
That said, however, the analyst also noted that there is a possibility of the sector being a "source" instead of a destination for new healthcare investment flows.
Newitter urged investors to favor names with 2026 catalysts driving durable revenue acceleration or out-of-favor near-term narratives.
Joanne Wuensch, a top 7% analyst from Citigroup maintains GKOS with a strong buy rating and raises their GKOS price target from $113.00 to $125.00, on Dec 11, 2025.
Allen Gong, a top 33% analyst from JP Morgan maintains GKOS with a strong buy rating and raises their GKOS price target from $110.00 to $120.00, on Oct 30, 2025.
Larry Biegelsen, a top 17% analyst from Wells Fargo maintains GKOS with a strong buy rating and raises their GKOS price target from $120.00 to $122.00, on Oct 30, 2025.
David Roman, a bottom 5% analyst from Goldman Sachs initiates coverage on GKOS with a strong buy rating and announces their GKOS price target of $103.00, on Oct 1, 2025.
You can dig deeper into what analysts are saying on the Glaukos stock forecast page.
Last year, GKOS revenue was $469.82M. During the past 5 year, GKOS's revenue has gone up by 16.64% per year. This was faster than the Medical Devices industry average of 10.86%.
You can research GKOS's earnings and revenue performance here.
In the past 12 months, insiders at GKOS have bought more shares than they have sold.
Thomas William Burns, CHAIRMAN CEO of GKOS, was the latest GKOS insider to buy. They bought $5,132,720.00 worth of GKOS shares on Feb 9, 2026.
Learn more about who owns GKOS stock here.
No, Glaukos doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
There are two primary types of orders:
Hit the Open button and your broker will place your order.
If you require more assistance buying stocks on eToro, click the how to video below:
Now that you own some GKOS shares, you'll want to keep up with your stock purchase.
Start a watchlist to keep tabs on your GKOS stock.
To reiterate, here are the 6 steps you need to take to buy Glaukos stock right now:
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Glaukos, add GKOS to your watchlist by clicking the button below.